Cargando…

Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

Detalles Bibliográficos
Autores principales:	Westerman, Mary E., Wood, Christopher G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475466/ https://www.ncbi.nlm.nih.gov/pubmed/32953837 http://dx.doi.org/10.21037/atm.2020.03.217

Ejemplares similares

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

TiVo hacks
por: Krikorian, Raffi
Publicado: (2003)

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
por: Molina, Ana M., et al.
Publicado: (2018)

Tivozanib for hepatocellular carcinoma: not likely a new option
por: Estrade, Florian, et al.
Publicado: (2020)

Fabrication of TiVO(4) photoelectrode for photoelectrochemical application
por: Alruwaili, Manal, et al.
Publicado: (2022)

Tivozanib in the treatment of renal cell carcinoma
por: Hepgur, Mehmet, et al.
Publicado: (2013)

Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis
por: Oh, Hyunwoo, et al.
Publicado: (2020)

Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
por: Rodenburg, RJ, et al.
Publicado: (2019)

A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma
por: Fountzilas, Christos, et al.
Publicado: (2020)

Milestones for development of tivozanib for kidney cancer therapy
por: Crescentini, Robert, et al.
Publicado: (2012)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
por: Cowey, C Lance
Publicado: (2013)

Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma
por: Yalcin, Suayib, et al.
Publicado: (2019)

Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma
por: Sakellakis, Minas, et al.
Publicado: (2023)

Synergistic Photoelectrochemical and Photocatalytic Properties of the Cobalt Nanoparticles-Embedded TiVO(4) Thin Film
por: Alruwaili, Manal, et al.
Publicado: (2023)

Tivozanib: a novel VGFR inhibitor for kidney cancer
por: Boyle, Helen
Publicado: (2013)

Editorial Commentary
por: Mosli, Hisham A.
Publicado: (2011)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Commentary: Open Your Mind to Open Chest Management
por: Kim, Myeong Su, et al.
Publicado: (2023)

Editorial Commentary: Paraneoplastic Syndromes
por: Katrak, Sarosh M
Publicado: (2021)

Commentary: Open globe injury: The Indian perspective
por: Moharana, Bruttendu, et al.
Publicado: (2022)

Commentary: Opening eyes to the mixed reality metaverse
por: Akkara, John D, et al.
Publicado: (2022)

JITC launches a new section: commentary and editorials
por: Capitini, Christian M., et al.
Publicado: (2015)

Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature
por: Caquelin, Laura, et al.
Publicado: (2022)

Editorial Commentary on the National Exit Examination
por: Prasad, Kameshwar
Publicado: (2020)

Editorial Commentary: Lipid Storage Myopathies
por: Khadilkar, Satish, et al.
Publicado: (2022)

Neurological Manifestations of Dengue- Editorial commentary
por: Chakravarty, Kamalesh, et al.
Publicado: (2021)

Commentary on the MID3 Good Practices Paper
por: Manolis, Efthymios, et al.
Publicado: (2017)

Commentary: Digital 3D atlas of ophthalmology
por: Akkara, John D, et al.
Publicado: (2022)

Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
por: Mihály, Zsuzsanna, et al.
Publicado: (2012)

Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model
por: Alanazi, Wael A., et al.
Publicado: (2023)

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
por: Palmer, D. H., et al.
Publicado: (2018)

Metabolic Signatures of Oxidative Stress in the Red Blood Cells: Editorial Commentary
por: Nwose, Ezekiel Uba
Publicado: (2015)

Editorial commentary: Native mitral valve infective endocarditis—Surgical concerns?
por: Kahrovic, Amila, et al.
Publicado: (2022)

Commentary: Do not close a door that opens a window!
por: Giambuzzi, Ilaria, et al.
Publicado: (2021)

Commentary: Congenital aortic arch reconstruction: Keeping the window open
por: Burkhart, Harold M., et al.
Publicado: (2021)

Commentary: Delayed sternal closure—an open and not-so-shut case
por: Eikelboom, Rachel, et al.
Publicado: (2020)

Commentary: Close it tight, so you can be sure it is open!
por: Barac, Yaron D.
Publicado: (2020)

Commentary: Aortic valve replacement in young adults: An open question
por: da Costa, Francisco Diniz Affonso
Publicado: (2021)

Joint Formal Comment for PLGE and Commentary for G3
Publicado: (2020)

Editorial Commentary: Understanding BCG Is the Key to Improving It
por: McShane, Helen
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mvs98187ahamc3g80519n801jq